← Leaderboards
Christine Heske
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalRhabdomyosarcomaPre-Clinical ModelPreclinical StudyPathway InteractionsChildhoodClinicBaseNeoplastic CellClinical TrialsInhibitor/AntagonistCombinatorialEnrollmentTranslatingSarcomaNovel TherapeuticsChildhood SarcomaGenetic ScreeningHeat-Shock Proteins 90Ewings SarcomaTranslationsScreening ProcedureStandard Of CareChemotherapy
Grant awards (16)
Development and translation of novel therapies for pediatric sarcoma$1,641,658
ZIA · FY2025 · CA · contact PI
Development and translation of novel therapies for pediatric sarcoma$1,753,582
ZIA · FY2024 · CA · contact PI
Development and translation of novel therapies for pediatric sarcoma$1,852,868
ZIA · FY2023 · CA · contact PI
Development of biologic based therapies for rhabdomyosarcoma$326,976
ZIA · FY2023 · CA · contact PI
Development and translation of novel therapies for pediatric sarcoma$1,274,610
ZIA · FY2022 · CA · contact PI
Development of biologic based therapies for rhabdomyosarcoma$224,931
ZIA · FY2022 · CA · contact PI
Development and translation of novel therapies for pediatric sarcoma$814,192
ZIA · FY2021 · CA · contact PI
Development of biologic based therapies for rhabdomyosarcoma$143,681
ZIA · FY2021 · CA · contact PI
Development and translation of novel therapies for pediatric sarcoma$711,980
ZIA · FY2020 · CA · contact PI
Development of biologic based therapies for rhabdomyosarcoma$125,644
ZIA · FY2020 · CA · contact PI
Development and translation of novel therapies for pediatric sarcoma$680,464
ZIA · FY2019 · CA · contact PI
Development of biologic based therapies for rhabdomyosarcoma$120,081
ZIA · FY2019 · CA · contact PI
Development and translation of novel therapies for pediatric sarcoma$526,808
ZIA · FY2018 · CA · contact PI
Development of biologic based therapies for rhabdomyosarcoma$175,602
ZIA · FY2018 · CA · contact PI
Development and translation of novel therapies for pediatric sarcoma$68,223
ZIA · FY2017 · CA · contact PI
Development of biologic based therapies for rhabdomyosarcoma$22,741
ZIA · FY2017 · CA · contact PI